Five things for pharma marketers to know: Tuesday, May 16, 2017
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
Opioids
Purdue Pharma hires new VP of public affairs, communications
Josephine Martin was previously EVP of public affairs at PhRMA.
Five things for pharma marketers to know: Thursday, April 20, 2017
Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O’Reilly leaves Fox
Pacira, Trinity Health aim to address opioid use in surgeries
Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.
Five things for pharma marketers to know: Thursday, March 30, 2016
Novartis CAR-T drug receives priority review; addiction center’s ad compares addiction to cancer; Arizona passes off-label law
Senate committee launches investigation into opioid marketing
The committee is seeking information about the companies’ sales and marketing strategies.
Five things for pharma marketers to know: Friday, February 24, 2017
PBMs’ use of “clawbacks” prompt lawsuits; Merck’s experimental antiviral drug prevents infection; EMA recommends Novartis’ lung-cancer combo drug
Five things for pharma marketers to know: Monday, February 13, 2016
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
Five things for pharma marketers to know: Tuesday, January 10, 2017
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet’s opioid Arymo ER gets FDA approval
Five things for pharma marketers to know: Thursday, December 15, 2016
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
